Streetwise Reports' Article Archives — July 2023 back to current month (9)
Co. Starts Using AI on Its Telehealth Platform (07/21/2023)
This telehealth company says it has started using artificial intelligence (AI) and machine learning (ML) with two of the clients on its platform.
The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report.
The healthcare tech firm's shares are underperforming despite two consecutive record quarters and a "landmark" contract win, noted an Echelon Capital Markets report.
Healthcare Tech Firm Sells Noncore Assets for $6M (07/10/2023)
The resulting upfront valuation gain equates to an estimated $0.02 per share, noted an Echelon Capital Markets report.
Approval Sought in Japan for New SARS-CoV-2 Vaccine (07/07/2023)
The vaccine developer's partner in Japan is already working on getting a manufacturing facility built there, noted an H.C. Wainwright & Co. report.
Co. Addresses Opioid Crisis Through Novel Platforms (07/07/2023)
This California biotech, developing products that prevent opioid abuse and overdose, gained coverage by an H.C. Wainwright & Co. analyst, an initiation report noted.
This company is expanding its telehealth platform into Mexico, where more than 10,000 new patients are expected to be on board by next June.
Recent clinical trial results show the oral interleukin-23 receptor to be a "cleaner" target than non-receptor tyrosine kinase 2, noted a BTIG report.
Despite having revenues below expectations, one analyst says this health company's Alzheimer's dementia diagnosis app is gaining commercial traction.